Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peritoneal Metastases From Gastric Cancer”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Ended earlyNCT01116791
What this trial is testing

Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer

Who this might be right for
Peritoneal CarcinomatosisGastrointestinal Cancer
Baki Topal 34
Not applicableEnded earlyNCT03349827
What this trial is testing

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Who this might be right for
Peritoneal Metastases From Gastric Cancer
Wuhan University 20
Testing effectiveness (Phase 2)UnknownNCT00454519
What this trial is testing

Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis

Who this might be right for
Stomach NeoplasmsColorectal NeoplasmsNeoplasm Metastasis+1 more
Wuhan University 60
Large-scale testing (Phase 3)UnknownNCT03179579
What this trial is testing

Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer

Who this might be right for
Gastric CancerPeritoneal Carcinomatosis
Shu-Zhong Cui 88
Testing effectiveness (Phase 2)Looking for participantsNCT07556640
What this trial is testing

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Who this might be right for
Gastric Cancer Stage IVPeritoneal Metastases From Gastric CancerGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital 74
Not applicableStudy completedNCT03604653
What this trial is testing

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Who this might be right for
Stomach CancerColorectal CancerAppendiceal Cancer+5 more
Holy Name Medical Center, Inc. 10
Not applicableLooking for participantsNCT07313579
What this trial is testing

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

Who this might be right for
Gastric Cancer (GC)HIPECPeritoneal Metastases From Gastric Cancer+1 more
Ukrainian Society of Clinical Oncology 200
Testing effectiveness (Phase 2)Looking for participantsNCT07133490
What this trial is testing

INTERACT Stomach-II

Who this might be right for
Peritoneal Metastases From Gastric Cancer
Erasmus Medical Center 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06283121
What this trial is testing

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Who this might be right for
Gastric Cancer, Metastatic
China Medical University, China 30
Early research (Phase 1)Active Not RecruitingNCT05277766
What this trial is testing

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Who this might be right for
Peritoneal CarcinomatosisPeritoneal MetastasesColorectal Cancer+5 more
University Hospital, Ghent 45
Testing effectiveness (Phase 2)Study completedNCT05185947
What this trial is testing

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

Who this might be right for
Gynecologic CancerGynecologic NeoplasmsPeritoneal Carcinomatosis+9 more
National Cancer Institute (NCI) 21